Obesity: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• GLP-1 170
• PPAR 0
• FTO 0
• AMPK 3
• GIP 20
• SGLT2 5
• STAT3 0
• SIRT1 0
• PI3K 0
• NRF2 0
• AKT 0
• mTOR 2
• NLRP3 3
• MAPK 0
• TP53 0
• TNF 0
• IL-6 1
• TLR4 0
• BDNF 2
• DPP-4 1
• JNK 0
• APOE 0
• ERK 0
• IL-17 1
• PTEN 0
• STING 0
• ACE2 0
• HIF-1 0
• PCSK9 0
• VEGF 0
• IL-1 0
• JAK 0
• PNPLA3 2
• YAP 0
• HMGB1 0
• CTNNB1 0
• HER2 0
• MMP-9 0
• PD-L1 0
• PINK1 0
• TFEB 0
• TREM2 0
• CCR5 0
• FGFR 0
• GPX4 0
• IGF1R 0
• IL-23 0
• METTL3 0
• PD-1 0
• STK11 0
• AR 0
• BCL-2 0
• CFTR 0
• COX-2 0
• HDAC 0
• EGFR 0
• HSP90 0
• MEK 0
• MYC 0
• PKM2 0

24 of 30+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Elucidating the role of maternal nutrient stores in the metabolism of the preimplantation embryo (MaterMeta)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Studying the role of Tbx-3 expressing neurons during obesity and ageing (OBrAgeing)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €226,421· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Selective Sensory Vagal Interface: a bionic platform for internal organ modulation (VisceraLink)

  Medizinische Universitaet Wien· Wien, Austria· EU contribution €2,210,625· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Metabolic disease heterogeneity definition, prevention and remission with targeted interventions (MEDIculous REMeDy)

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Germany· EU contribution €4,437,236· until Dec 2030· 11 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Bridging Chronobiology and Physiology through Expert Training (ChronoBridge)

  Ecole Polytechnique Federale de Lausanne· Lausanne, Switzerland· EU contribution €3,885,022· until Dec 2030· 9 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Modelling endocrine-Immune interactions in response to food Proteins (IMMPRO).

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €194,075· until Aug 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  A Pan-population study of obesity, risk and metabolic architecture (PANORAMA)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €2,491,440· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting Cardiovascular Disease with Microbiota-derived Bioactive Compounds (DIETherapy)

  Goeteborgs Universitet· Goeteborg, Sweden· EU contribution €236,340· until Aug 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unveiling Dynamic Autonomic Regulation in health and disease through Network Physiology (DARNePh)

  Univerzita Komenskeho V Bratislave· Bratislava 1, Slovakia· EU contribution €172,942· until Aug 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Unique and overlapping functions and CNS sites of action for NK2R and LepR signaling (LINK2CNS)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €423,946· until Aug 2029· 2 countries

10 of 127 running projects, newest first. Listed amounts together: €430.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Updated 16 Oct 2026

  “poor accrual and funding issues”Registry text, quoted unchanged. Source

• Terminated

  A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

  NCT07553299· Verdiva Bio Dev Limited· Updated 13 Oct 2026

  “The Study Sponsor made a business decision not to continue the study. The decision was not based on safety findings.”Registry text, quoted unchanged. Source

• Terminated

  RESCUE: Discontinuation of GLP-1

  NCT07190794· Boston Scientific Corporation· Updated 24 Jul 2026

  “Business decision”Registry text, quoted unchanged. Source

• Withdrawn

  GLP-1 RA on Liver OMICS in MASLD

  NCT06982378· Medical College of Wisconsin· Updated 13 Jul 2026

  “no grant approved”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluation of the Efficacy of the Composite WM Formula in Body Weight Change

  NCT07097974· TCI Co., Ltd.· Updated 13 May 2026

  “based on an overall assessment of feasibility and strategic considerations”Registry text, quoted unchanged. Source

• Suspended

  Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

  NCT06171152· University of Chicago· Updated 30 Mar 2026

  “Study pending amendment”Registry text, quoted unchanged. Source

• Withdrawn

  The Effects of Semaglutide on Body Composition and Performance in Military Personnel

  NCT06468748· United States Army Research Institute of Environmental Medicine· Updated 19 Dec 2025

  “lack of funding”Registry text, quoted unchanged. Source

• Terminated

  A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

  NCT06000891· Zealand Pharma· Updated 25 Apr 2025

  “Decision by Sponsor; LSLV was completed on 21-Mar-2025 as planned.”Registry text, quoted unchanged. Source

• Terminated

  Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

  NCT06515418· BioAge Labs, Inc.· Updated 13 Mar 2025

  “Dosing of both study drugs has been discontinued due to observation of liver transaminitis without clinically significant symptoms in some subjects receiving azelaprag. All participant visits have been completed.”Registry text, quoted unchanged. Source

• Withdrawn

  Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

  NCT04885634· Axel Brandes· Updated 3 Nov 2023

  “Not received funding.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

  NCT07517042· Shanghai Zhongshan Hospital· Source

• 24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor

  NCT07929233· Portuguese Oncology Institute, Coimbra· Source

• Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

  NCT07830329· Regeneron Pharmaceuticals· Source

• GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

  NCT06162715· Vanderbilt University Medical Center· Source

• A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

  NCT07775404· AstraZeneca· Source

• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  NCT07575399· Amgen· Source

• Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

  NCT07685808· Regeneron Pharmaceuticals· Source

• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

  NCT07575932· Pfizer· Source

• A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

  NCT06973720· Pfizer· Source

• A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

  NCT07919678· Pfizer· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 21
• Organoids 10
• Mendelian Randomization Analysis 179
• CRISPR-Cas Systems 7
• Gene Expression Profiling 144
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 4
• Exome Sequencing 19
• Proteomics 127
• Metabolomics 190
• Mass Spectrometry 28
• Flow Cytometry 16
• Immunohistochemistry 41
• Xenograft Model Antitumor Assays 15
• Positron-Emission Tomography 25
• Magnetic Resonance Imaging 258
• Machine Learning 155
• Deep Learning 20
• Cohort Studies 1013
• Genome-Wide Association Study 202

• Polygonatum odoratum (Mill.) Druce: A Review of Traditional Uses, Phytochemistry, Mass Spectrometric Fragmentation, Pharmacology, Toxicology, and Q-Marker Prediction.

  Drug Des Devel Ther, Sept 2026

• Adipose tissue metabolic dysregulation in diet-induced obesity: insights from UHPLC-HRMS-based metabolomics.

  PeerJ, Sept 2026

• Integrating 3D Chromatography With Orbitrap Mass Spectrometry to Profile the Chemical Constituents in JTTZ Formula and Investigate Plasma Pharmacokinetic Changes in Obese Rats.

  Phytochem Anal, Jun 2026

• Characterizing the molecular signature of obesity through urine metabolomics in a large Chinese population.

  J Chromatogr B Analyt Technol Biomed Life Sci, Jun 2026

• OHR-LCMS based chemical profiling and dietary effects of morel mushroom Morchella esculenta (L.) Pers. on diet-induced obese zebrafish: Insights from physiological, biochemical, histological and ATR-FTIR spectroscopy.

  Fitoterapia, Mar 2026

• Ultra-sensitive analysis of exhaled biomarkers in ozone-exposed mice via PAI-TOFMS assisted with machine learning algorithms.

  J Hazard Mater, Mar 2024

• Association of polychlorinated biphenyls with vitamin D in female subjects.

  Environ Res, Jun 2023

• SPM pathway marker analysis of the brains of obese mice in the absence and presence of eicosapentaenoic acid ethyl esters.

  Prostaglandins Leukot Essent Fatty Acids, Nov 2021

• Beneficial effects of eicosapentaenoic acid on the metabolic profile of obese female mice entails upregulation of HEPEs and increased abundance of enteric Akkermansia muciniphila.

  Biochim Biophys Acta Mol Cell Biol Lipids, Oct 2021

• Essential trace elements in Norwegian obese patients before and 12 months after Roux-en-Y gastric bypass surgery: Copper, manganese, selenium and zinc.

  J Trace Elem Med Biol, Sept 2020

See which targets of this disease your abstract mentions, and go to the people working on them.